Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland

Reuters

2025/08/13

Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland

Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced that its non-invasive colorectal cancer screening test, ColoAlert®, has been officially registered and granted marketing approval by Swissmedic, the Swiss agency for therapeutic products. This approval allows ColoAlert to be marketed in Switzerland, following a partnership with the Swiss diagnostic laboratory, labor team w ag. The test, which detects colorectal cancer tumor DNA and other biomarkers in stool samples with high sensitivity, aims to improve early detection and increase participation in screening programs in Switzerland, where less than half of the eligible population currently participates in such programs. This milestone is part of Mainz Biomed's broader strategy to expand access to reliable colorectal cancer early detection solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2182912_de), on August 13, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2559604979"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559604979\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559604979?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-13 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559604979","market":"us","top_or_hot":-1,"title":"Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced that its non-invasive colorectal cancer screening test, ColoAlert®, has been officially registered and granted marketing approval by Swissmedic, the Swiss agency for therapeutic products. This approval allows ColoAlert to be marketed in Switzerland, following a partnership with the Swiss diagnostic laboratory, labor team w ag. The test, which detects colorectal cancer tumor DNA and other biomarkers in stool samples with high sensitivity, aims to improve early detection and increase participation in screening programs in Switzerland, where less than half of the eligible population currently participates in such programs. This milestone is part of Mainz Biomed's broader strategy to expand access to reliable colorectal cancer early detection solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2182912_de), on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-13 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced that its non-invasive colorectal cancer screening test, ColoAlert®, has been officially registered and granted marketing approval by Swissmedic, the Swiss agency for therapeutic products. This approval allows ColoAlert to be marketed in Switzerland, following a partnership with the Swiss diagnostic laboratory, labor team w ag. The test, which detects colorectal cancer tumor DNA and other biomarkers in stool samples with high sensitivity, aims to improve early detection and increase participation in screening programs in Switzerland, where less than half of the eligible population currently participates in such programs. This milestone is part of Mainz Biomed's broader strategy to expand access to reliable colorectal cancer early detection solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2182912_de), on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYNZ","symbol_name":"Mainz Biomed NV","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL2XFlYt:1","article_id":"2559604979","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559604979","pubTimestamp":1755086628,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced that its non-invasive colorectal cancer screening test, ColoAlert, has been officially registered and granted marketing approval by Swissmedic, the Swiss agency for therapeutic products. This approval allows ColoAlert to be marketed in Switzerland, following a partnership with the Swiss diagnostic laboratory, labor team w ag. The test, which detects colorectal cancer tumor DNA and other biomarkers in stool samples with high sensitivity, aims to improve early detection and increase participation in screening programs in Switzerland, where less than half of the eligible population currently participates in such programs. This milestone is part of Mainz Biomed's broader strategy to expand access to reliable colorectal cancer early detection solutions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYNZ":"Mainz Biomed NV","BK4139":"生物科技"},"translate_title":"Mainz Biomed NV的ColoAlert获得Swissmedic批准®瑞士的癌症筛查测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYNZ":0.9},"content_text":"Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland\n    \n\n        Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced that its non-invasive colorectal cancer screening test, ColoAlert®, has been officially registered and granted marketing approval by Swissmedic, the Swiss agency for therapeutic products. This approval allows ColoAlert to be marketed in Switzerland, following a partnership with the Swiss diagnostic laboratory, labor team w ag. The test, which detects colorectal cancer tumor DNA and other biomarkers in stool samples with high sensitivity, aims to improve early detection and increase participation in screening programs in Switzerland, where less than half of the eligible population currently participates in such programs. This milestone is part of Mainz Biomed's broader strategy to expand access to reliable colorectal cancer early detection solutions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2182912_de), on August 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}